drugset / Trial / NCT00088270

A Study of OSI-7904L Versus 5-FU/LV as Treatment in Patients With Biliary Tract Cancer

NCT00088270 ↗

Phase 2 Completed 58 enrolled OSI Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

Multi-center, randomized Phase II study to evaluate the efficacy and safety of OSI-7904Lversus 5 FU/LV in biliary tract cancer.

Timeline

Start
2004-08
Primary completion
—
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Leucovorin Small molecule — —
Subject OSI-7904 Small molecule — —
Subject fluorouracil Small molecule — —